Results 151 to 160 of about 131,040 (312)

Prognostic value of metabolic tumor volume of pretreatment 18F-FAMT PET/CT in non-small cell lung Cancer [PDF]

open access: yes, 2019
学位記番号 ...
Kumasaka, Soma   +2 more
core  

Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis

open access: yesEuropean Heart Journal-Cardiovascular Imaging, 2018
E. Wicks   +11 more
semanticscholar   +1 more source

Small Intestinal Metastasis From Pulmonary Large Cell Carcinoma Detected by Capsule Endoscopy and Balloon‐assisted Endoscopy, Followed by Early Surgical Resection: A Case Report

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Metastasis of lung cancer to the small intestine is rare and often diagnosed only after life‐threatening complications such as perforation or obstruction. We report a case of small intestinal metastasis from pulmonary large cell carcinoma, diagnosed using balloon‐assisted endoscopy (BAE) performed for obscure gastrointestinal bleeding (OGIB ...
Yoshihiro Yokota   +9 more
wiley   +1 more source

18F-Fluorodeoxyglucose Imaging for Assessing Cardiovascular Inflammation

open access: yesDiagnostics
Cardiovascular inflammation has recently emerged as a critical issue across various cardiovascular diseases. Various non-invasive imaging modalities are applied for assessing cardiovascular inflammation. Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is a valuable non-invasive imaging tool for identifying active cardiovascular ...
Nagara Tamaki   +2 more
openaire   +3 more sources

The Diagnostic Value of PET/CT and MRI in Head and Neck Cancer of Unknown Primary

open access: yesLaryngoscope Investigative Otolaryngology, Volume 11, Issue 2, April 2026.
PET/CT demonstrates a higher diagnostic yield than MRI in detecting primary tumors in patients undergoing diagnostic work‐up for head and neck cancer of unknown primary origin. However, combining PET/CT and MRI improves overall detection rates and enhances soft tissue evaluation.
Signe Bergliot Nielsen   +8 more
wiley   +1 more source

Multiparametric MRI to Predict Response to Irreversible Electroporation Plus Anti‐PD‐1 Immunotherapy in Pancreatic Ductal Adenocarcinoma

open access: yesMagnetic Resonance in Medicine, Volume 95, Issue 4, Page 2266-2276, April 2026.
ABSTRACT Purpose To investigate contrast‐enhanced T1‐weighted MRI and diffusion‐weighted magnetic resonance imaging (DWI) for early prediction of tumor response to combined irreversible electroporation (IRE) and anti‐PD‐1 immunotherapy. Methods Murine pancreatic ductal adenocarcinoma (PDAC) cells KRAS* were inoculated into the pancreas of C57BL/6 mice.
Qizhen Cao   +9 more
wiley   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

open access: yesEuropean Journal of Haematology, Volume 116, Issue 4, Page 357-367, April 2026.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta   +12 more
wiley   +1 more source

Next‐generation sequencing‐based IG clonality analysis to discriminate reactive infiltrates from minimal lymphoma involvement in paired lymphoma and bone marrow biopsies; a EuroClonality‐NGS Working Group study

open access: yesHistopathology, Volume 88, Issue 5, Page 1059-1074, April 2026.
Next‐generation sequencing (NGS) immunoglobulin clonality analysis can help resolve ambiguous bone marrow staging biopsies for B‐cell lymphoma. In this study, paired analysis of the primary lymphoma and bone marrow helped to detect lymphoma involvement in cases with inconclusive morphology and immunohistochemistry, making it a valuable tool for ...
Michiel van den Brand   +6 more
wiley   +1 more source

Durvalumab combined with concurrent chemoradiotherapy in patients with limited‐stage small cell lung cancer: A prospective, single‐arm, phase 2 clinical trial

open access: yesCancer, Volume 132, Issue 6, 15 March 2026.
Abstract Background The current standard treatment for limited‐stage small cell lung cancer (LS‐SCLC) is concurrent chemoradiotherapy (cCRT) plus consolidation immunotherapy, with or without prophylactic cranial irradiation (PCI). However, it remains unknown whether administering immunotherapy concurrently with chemoradiotherapy confers additional ...
Chunyang Song   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy